Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
1(50%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
1
50%
Ph not_applicable
1
50%

Phase Distribution

1

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution2 total trials
Phase 1Safety & dosage
1(50.0%)
N/ANon-phased studies
1(50.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

2

all time

Status Distribution
Active(1)
Completed(1)

Detailed Status

Completed1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
2
Active
1
Success Rate
100.0%
Most Advanced
Phase 1

Trials by Phase

Phase 11 (50.0%)
N/A1 (50.0%)

Trials by Status

completed150%
recruiting150%

Recent Activity

1 active trials
Showing 2 of 2
recruitingphase_1

Imaging Study of [89Zr]DFO-YS5 for Detecting CD46 Positive Malignancy in Multiple Myeloma

NCT05892393
completednot_applicable

PET Scan Combined With CT Scan in Evaluating Treatment Response in Patients Undergoing Treatment for Bone Cancer or Soft Tissue Sarcoma

NCT00335751

Clinical Trials (2)

Showing 2 of 2 trials
NCT05892393Phase 1

Imaging Study of [89Zr]DFO-YS5 for Detecting CD46 Positive Malignancy in Multiple Myeloma

Recruiting
NCT00335751Not Applicable

PET Scan Combined With CT Scan in Evaluating Treatment Response in Patients Undergoing Treatment for Bone Cancer or Soft Tissue Sarcoma

Completed

All 2 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
2